These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer. Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795 [TBL] [Abstract][Full Text] [Related]
8. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363 [TBL] [Abstract][Full Text] [Related]
9. TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity. Stone JD; Harris DT; Kranz DM Curr Opin Immunol; 2015 Apr; 33():16-22. PubMed ID: 25618219 [TBL] [Abstract][Full Text] [Related]
10. Measuring Chimeric Antigen Receptor T Cells (CAR T Cells) Activation by Coupling Intracellular Cytokine Staining with Flow Cytometry. Xu C; Yin Y Methods Mol Biol; 2020; 2108():159-165. PubMed ID: 31939179 [TBL] [Abstract][Full Text] [Related]
11. Approaches of T Cell Activation and Differentiation for CAR-T Cell Therapies. Schwab RD; Bedoya DM; King TR; Levine BL; Posey AD Methods Mol Biol; 2020; 2086():203-211. PubMed ID: 31707678 [TBL] [Abstract][Full Text] [Related]
12. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. Torres Chavez A; McKenna MK; Canestrari E; Dann CT; Ramos CA; Lulla P; Leen AM; Vera JF; Watanabe N J Immunother Cancer; 2019 Nov; 7(1):330. PubMed ID: 31779709 [TBL] [Abstract][Full Text] [Related]
13. Cholesterol Esterification Enzyme Inhibition Enhances Antitumor Effects of Human Chimeric Antigen Receptors Modified T Cells. Zhao L; Li J; Liu Y; Kang L; Chen H; Jin Y; Zhao F; Feng J; Fang C; Zhu B; Ding S; Yu L; Wei Y; Zhou J J Immunother; 2018; 41(2):45-52. PubMed ID: 29252915 [TBL] [Abstract][Full Text] [Related]
14. T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand. Choudhuri K; Wiseman D; Brown MH; Gould K; van der Merwe PA Nature; 2005 Jul; 436(7050):578-82. PubMed ID: 16049493 [TBL] [Abstract][Full Text] [Related]
15. TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens. Akatsuka Y Front Immunol; 2020; 11():257. PubMed ID: 32184779 [TBL] [Abstract][Full Text] [Related]
16. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy. Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878 [TBL] [Abstract][Full Text] [Related]
17. TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells. Li D; Hu Y; Jin Z; Zhai Y; Tan Y; Sun Y; Zhu S; Zhao C; Chen B; Zhu J; Chen Z; Chen S; Li J; Liu H Leukemia; 2018 Sep; 32(9):2012-2016. PubMed ID: 30046161 [No Abstract] [Full Text] [Related]
18. An Ig Transmembrane Domain Motif Improves the Function of TCRs Transduced in Human T Cells: Implications for Immunotherapy. D'Apice L; Cuccaro F; Varriale S; Cipria D; Sartorius R; Circosta P; Cignetti A; Salerno M; Coscia MR; Oreste U; Marzullo VM; Martini G; Acuto O; De Berardinis P J Immunother; 2019 May; 42(4):97-109. PubMed ID: 30865026 [TBL] [Abstract][Full Text] [Related]
19. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies. Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584 [TBL] [Abstract][Full Text] [Related]
20. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer. Anderson KG; Voillet V; Bates BM; Chiu EY; Burnett MG; Garcia NM; Oda SK; Morse CB; Stromnes IM; Drescher CW; Gottardo R; Greenberg PD Cancer Immunol Res; 2019 Sep; 7(9):1412-1425. PubMed ID: 31337659 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]